Blood Outgrowth Endothelial Cells (BOECs) and Megakaryocytes (MKs) for in vitro studies of hemostatic and secretory function.

Blood Outgrowth Endothelial Cells (BOECs) and Megakaryocytes (MKs) for in vitro studies of hemostatic and secretory function. - Cellular function in BOECs and MKs

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56840

Enrollment

700

Registered

2020-08-12

Start date

2020-04-01

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inherited platelet function disorders hemostatic defects

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: Patients • Prior diagnosis of VWD, low VWF, inherited platelet function defects, bleeding of unknown cause or genetic disorders in which dysfunction of the secretory pathway has been implicated in disease pathogenesis. • For patients >=16 years old; written informed consent • For patients 12-15 years old; written informed consent from both the patient and their parent(s)/legal guardian(s) • For patients

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: • Unable to give written informed consent. • Use of medication that can compromise platelet function or hemostasis.

Design outcomes

Primary

Measure	Time frame
A maximum of seventy milliliters of blood will be drawn for the isolation of PBMCs, platelets, plasma and DNA. Several parameters will be measured in plasma to characterize the hemostatic and angiogenic profile. BOECs, iPSC-ECs/MKs and CD34+-derived primary MKs will be characterized in vitro. Protein expression profiles will be determined by whole proteome mass spectrometry. DNA will be genotyped for SNPs and mutations in VWF and VWF associated genes.	—

Measure

Time frame

A maximum of seventy milliliters of blood will be drawn for the isolation of PBMCs, platelets, plasma and DNA. Several parameters will be measured in plasma to characterize the hemostatic and angiogenic profile. BOECs, iPSC-ECs/MKs and CD34+-derived primary MKs will be characterized in vitro. Protein expression profiles will be determined by whole proteome mass spectrometry. DNA will be genotyped for SNPs and mutations in VWF and VWF associated genes.

—

Countries

Netherlands

Outcome results